Friday, 25 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

Resolutions from the Annual General Meeting of Novo Nordisk A/S

View original at finance.yahoo.com
Resolutions from the Annual General Meeting of Novo Nordisk A/S Novo Nordisk A/S Bagsværd, Denmark, 26 March 2026 – Today, Novo Nordisk A/S held its Annual General Meeting…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2025 was a year of profound transformation for Novo Nordisk

    60% confidence

  • Novo Nordisk is reshaping its traditional approach to patient care and market access, needing to meet patients where they are

    60% confidence

  • The year ahead will test Novo Nordisk's determination and capabilities, but the company faces it with confidence

    60% confidence

  • Novo Nordisk's renewed focus, strengthened competencies and commitment to people with serious chronic diseases position them well for challenges and opportunities ahead

    60% confidence

Data points we hold from this source

Novo Nordisk A/S · final dividend per share7.95 DKK
Novo Nordisk A/S · dividend per share11.70 DKK
Novo Nordisk A/S · share par value0.10 DKK
Novo Nordisk A/S · authorized share repurchase limit10 percent
Novo Nordisk A/S · authorized share capital increase44650000 DKK
Novo Nordisk A/S · interim dividend per share3.75 DKK
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Resolutions from the Annual General Meeting of Novo Nordisk A/S — Source | Via News | ViaNews EU